BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30693001)

  • 21. Experimental cerebral malaria pathogenesis--hemodynamics at the blood brain barrier.
    Nacer A; Movila A; Sohet F; Girgis NM; Gundra UM; Loke P; Daneman R; Frevert U
    PLoS Pathog; 2014 Dec; 10(12):e1004528. PubMed ID: 25474413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells.
    Lundie RJ; de Koning-Ward TF; Davey GM; Nie CQ; Hansen DS; Lau LS; Mintern JD; Belz GT; Schofield L; Carbone FR; Villadangos JA; Crabb BS; Heath WR
    Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14509-14. PubMed ID: 18799734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8
    Ghazanfari N; Gregory JL; Devi S; Fernandez-Ruiz D; Beattie L; Mueller SN; Heath WR
    J Immunol; 2021 Sep; 207(6):1578-1590. PubMed ID: 34400523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ T Cells Induce Fatal Brainstem Pathology during Cerebral Malaria via Luminal Antigen-Specific Engagement of Brain Vasculature.
    Swanson PA; Hart GT; Russo MV; Nayak D; Yazew T; Peña M; Khan SM; Janse CJ; Pierce SK; McGavern DB
    PLoS Pathog; 2016 Dec; 12(12):e1006022. PubMed ID: 27907215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of CD8
    Barrera V; Haley MJ; Strangward P; Attree E; Kamiza S; Seydel KB; Taylor TE; Milner DA; Craig AG; Couper KN
    Front Immunol; 2019; 10():1747. PubMed ID: 31396236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
    Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
    Front Immunol; 2018; 9():997. PubMed ID: 29867974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
    Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
    Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
    [No Abstract]   [Full Text] [Related]  

  • 28. Disruption of Parasite hmgb2 Gene Attenuates Plasmodium berghei ANKA Pathogenicity.
    Briquet S; Lawson-Hogban N; Boisson B; Soares MP; Péronet R; Smith L; Ménard R; Huerre M; Mécheri S; Vaquero C
    Infect Immun; 2015 Jul; 83(7):2771-84. PubMed ID: 25916985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules.
    Singh RP; La Cava A; Hahn BH
    J Immunol; 2008 Feb; 180(4):2069-80. PubMed ID: 18250412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFNAR1 controls progression to cerebral malaria in children and CD8+ T cell brain pathology in Plasmodium berghei-infected mice.
    Ball EA; Sambo MR; Martins M; Trovoada MJ; Benchimol C; Costa J; Antunes Gonçalves L; Coutinho A; Penha-Gonçalves C
    J Immunol; 2013 May; 190(10):5118-27. PubMed ID: 23585679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA.
    Palomo J; Fauconnier M; Coquard L; Gilles M; Meme S; Szeremeta F; Fick L; Franetich JF; Jacobs M; Togbe D; Beloeil JC; Mazier D; Ryffel B; Quesniaux VF
    Eur J Immunol; 2013 Oct; 43(10):2683-95. PubMed ID: 23780878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria.
    Belnoue E; Kayibanda M; Vigario AM; Deschemin JC; van Rooijen N; Viguier M; Snounou G; Rénia L
    J Immunol; 2002 Dec; 169(11):6369-75. PubMed ID: 12444144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-12Rβ2 is essential for the development of experimental cerebral malaria.
    Fauconnier M; Palomo J; Bourigault ML; Meme S; Szeremeta F; Beloeil JC; Danneels A; Charron S; Rihet P; Ryffel B; Quesniaux VF
    J Immunol; 2012 Feb; 188(4):1905-14. PubMed ID: 22238458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of histamine-mediated signaling confers significant protection against severe malaria in mouse models of disease.
    Beghdadi W; Porcherie A; Schneider BS; Dubayle D; Peronet R; Huerre M; Watanabe T; Ohtsu H; Louis J; Mécheri S
    J Exp Med; 2008 Feb; 205(2):395-408. PubMed ID: 18227221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
    Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
    J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
    Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a Novel CD4
    Fernandez-Ruiz D; Lau LS; Ghazanfari N; Jones CM; Ng WY; Davey GM; Berthold D; Holz L; Kato Y; Enders MH; Bayarsaikhan G; Hendriks SH; Lansink LIM; Engel JA; Soon MSF; James KR; Cozijnsen A; Mollard V; Uboldi AD; Tonkin CJ; de Koning-Ward TF; Gilson PR; Kaisho T; Haque A; Crabb BS; Carbone FR; McFadden GI; Heath WR
    J Immunol; 2017 Dec; 199(12):4165-4179. PubMed ID: 29084838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactive glia promote development of CD103
    Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
    Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.